Sphingolipids and Atherosclerosis

Area of Science:

• Biochemistry
• Cardiovascular Biology
• Metabolomics

Background:

• Atherosclerosis is a complex inflammatory disease driven by lipid accumulation and endothelial dysfunction.
• Sphingolipids are crucial membrane components and signaling molecules involved in cellular processes.
• Dysregulation of sphingolipid metabolism is increasingly implicated in cardiovascular pathology.

Purpose of the Study:

• To review the role of sphingolipid metabolism in the development of atherosclerosis.
• To integrate findings from human and mouse studies on the endothelium-lipoprotein-atherogenic plaque axis.
• To explore the potential of sphingolipid biomarkers for clinical application.

Main Methods:

• Literature review integrating human and mouse model studies.
• Analysis of sphingolipid involvement in key atherogenic stages.
• Evaluation of current sphingolipid biomarkers.

Main Results:

• Sphingolipids (ceramide, sphingomyelin, etc.) are central to atherogenesis.
• These molecules participate in lipoprotein modification, endothelial dysfunction, and plaque formation.
• Advances in sphingolipid biomarkers show clinical promise but have limitations.

Conclusions:

• Sphingolipid metabolism is a critical determinant of atherosclerosis progression.
• Targeting sphingolipid pathways may offer novel therapeutic strategies.
• Further research is needed to validate sphingolipid biomarkers for clinical use.